TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03308721
Drug: NNC9204-1177 A 1.0 mg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will get 1 or more injections into the skin of the stomach area once each week for 12 weeks.~Dose gradually increased to 6000 μg.
Study: NCT03308721
Drug: PLACEBO
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will get 1 or more injections into the skin of the stomach area once each week for 12 weeks.
Study: NCT01160822
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets for oral administration
Study: NCT01160822
Drug: Placebo to Naproxen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets for oral administration
Study: NCT03037580
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (sugar pill) for TID oral administration
Study: NCT00152269
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, Tablet, oral Daily for 12 months
Study: NCT00648960
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose 500 mg immediate-release oral tablet
Study: NCT00648960
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose 500 mg immediate-release oral dose
Study: NCT00268853
Drug: CPOP-R
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide 750 mg/m2, pixantrone 150 mg/m2, vincristine 1.4 mg/m2, rituximab 375 mg.m2 on Day 1 of a 21 day cycle, for 8 cycles Prednisone 100 mg/day on Day 1-5 of a 21 day cycle for 8 cycles
Study: NCT00268853
Drug: CHOP-R
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, vincristine 1.4 mg/m2, rituximab 375 mg.m2 on Day 1 of a 21 day cycle, for 8 cycles Prednisone 100 mg/day on Day 1-5 of a 21 day cycle for 8 cycles
Study: NCT00614705
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral capsule form, once daily for 28 days
Study: NCT04448756
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received placebo tablets matched to M5049 daily for 14 days.
Study: NCT00794443
Drug: YM529 / ONO-5920
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT01479829
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib is a nonsteroidal anti-inflammatory drug
Study: NCT01479829
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is a manufactured capsule with no active ingredient
Study: NCT04541771
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: expressed breast milk/formula milk plus normal saline drop from the beginning of enteral feedings till the baby attain full feeds
Study: NCT00740857
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 placebo gels capsules delivered as a single dose.
Study: NCT00740857
Drug: ibuprofen Formulation 1
Normalized name: ibuprofen 0.1 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 marketed ibuprofen gels
Study: NCT00740857
Drug: ibuprofen Formulation 2
Normalized name: ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 marketed ibuprofen gels
Study: NCT00217178
Drug: Vitamins: Folic acid, B6, B12
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04609878
Drug: BFF MDI 320/9.6 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide and formoterol fumarate metered dose inhaler
Study: NCT02527421
Drug: DFD01 Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: DFD-01 (betamethasone dipropionate) Spray, 0.05%
Study: NCT00790270
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 400 mg every 8 hours as needed
Study: NCT00790270
Drug: Ibuprofen plus Cyclobenzaprine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 400 mg plus cyclobenzaprine 5 mg every 8 hours as needed
Study: NCT00282308
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01584440
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule
Study: NCT01237899
Drug: LY2623091
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT01237899
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT01237899
Drug: Eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT00576329
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical use before surgery
Study: NCT00337675
Drug: Comparator: Placebo (unspecified)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Pbo) qd + episode driven supplemental Pbo for 12 days for a 52-wk treatment period.
Study: NCT00065169
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02036970
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01871740
Drug: Enalapril maleate and folic acid tablets
Normalized name: Enalapril Maleate
DrugBank: Enalapril (DB00584)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enalapril maleate and folic acid tablets, (10mg/0.8mg)/tablet, taken orally and once daily for a maximum of 5 years. Combination with other anti-hypertension drugs are allowed.
Study: NCT02350478
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subject will receive placebo orally once daily for 12 weeks.
Study: NCT00846963
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo given in the same amount that ursodiol would be given, depending on enteral feeding and weight. It is also given three times a day, until cholestasis resolution.
Study: NCT00218218
Drug: placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00771953
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo tablets will be provided as white or off-white film-coated tablets to be taken every day
Study: NCT01254708
Drug: Ambisome ®
Approvals — FDA: no, EMA: no, PMDA: no
Description: liposomal amphotericin B
Study: NCT01254708
Drug: Regular standard of care medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug for this group is at the physician's discretion. Patients in this group receive the standard of care medication currently implemented at the Institution. Example would be voriconazole
Study: NCT01086358
Drug: Triptan
Normalized name: Oxitriptan
DrugBank: Oxitriptan (DB02959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual prescribed triptans may include:sumatriptan, rizatriptan, naratriptan, almotriptan, eletriptan, zolmitriptan
Study: NCT01086358
Drug: Treximet 85Mg-500Mg Tablet
Normalized name: Treximet 85mg-500mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treximet is 85 mg sumatriptan plus 500 mg naproxen sodium
Study: NCT00578292
Drug: Campath 1H
Approvals — FDA: no, EMA: no, PMDA: no
Description: Per institutional guidelines Days -5 through -2
Study: NCT00578292
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 mg/kg Days -5 through -2
Study: NCT04044937
Drug: F-18 Fluoroethyltyrosine (FET)
Normalized name: FET F-18
DrugBank: FET F-18 (DB15405)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients given an injected dose of 4 to 7 millicurie (mCi) of FET per scan. The radiopharmaceutical will be administered while the patient is in the PET scanner
Study: NCT01924949
Drug: LDV/SOF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ledipasvir (LDV)/sofosbuvir (SOF) 90/400 mg FDC tablet administered orally once daily
Study: NCT02614599
Drug: BP22042013
Approvals — FDA: no, EMA: no, PMDA: no
Description: This group of patients receive 2.000 kilo-calories diet (60 g. carbohydrates, 144 gr of fat and 107 gr of proteins), including 2 protein shakes.
Study: NCT01302249
Drug: AR-12286 Ophthalmic Solution 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00162019
Drug: Human Plasma-Derived Coagulation Factor VIII Concentrate (Virus Inactivated by Polysorbate 80 Treatment and Vapor Heat Treatment)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00006205
Drug: Placebo + cognitive behavioral therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT02615639
Drug: HPDC-T cells & IFN-a-2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: experimental groups will be given HPDC-T cells \& IFN-a-2a. HPDC-T cells will be given for 24 weeks on the basis of anti-HBV therapy ,and IFN-a-2a 180ug subcutaneous injection every week
Study: NCT01262989
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: tamsulosin hydrochloride 0,4 mg (Synthon BV)
Study: NCT01262989
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: tamsulosin 0,4 mg (Boehringer Ingelheim)
Study: NCT04380519
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline (0.9% Sodium Chloride solution for Injection), in the market package
Study: NCT03005899
Drug: SyB P-1501
Normalized name: P
Approvals — FDA: no, EMA: no, PMDA: no
Description: After extubation and adequate titration by Fentanyl intravenous injection, the investigational product is applied to outer upper arm or chest on patient who confirmed treatment eligibility. Fentanyl 40 μg per dose is delivered over a 10-minute period by pressing the dosing button by the subject as needed. The 10-minute dosing period is a system lock-out time, allowing for a maximum of 6 doses per hour. One system is operable for 24 hours or until 80 doses are delivered, whichever occurs first.~Duration of application of the investigational product is 24 hours. Duration of application may be extended for up to 72 hours or until the third system is used, whichever occurs first, if the patient requests it and the specified tests can be performed
Study: NCT03005899
Drug: SyB P-1501 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical to SyB P-1501 containing hydrogel that contains the active ingredient fentanyl HCI in its structure and appearance but production of an electric current and subsequent drug administration by iontophoresis are prevented because of its modified circuit.
Study: NCT00635219
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules; daily; orally
Study: NCT00244543
Drug: R89674 (generic name not yet established)
Normalized name: forget-me-not extract
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04349800
Drug: KVD900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active
Study: NCT04349800
Drug: Placebo to KVD900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00262626
Drug: Intraocular pressure reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01191762
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 tablets with each meal
Study: NCT03331640
Drug: FOLFIRI Protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan 180 mg /m2 5-FU 400 mg/m2 (bolus) + 2400 mg/m2 as 46 hour infusion Na folinic acid 200 mg/m2 Cycle q2w
Study: NCT00397917
Drug: Folic acid: 4 mg versus 0.4 mg per day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Folic acid
Study: NCT01617746
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: bd for two weeks
Study: NCT03144934
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is the placebo of GX-I7 described above.
Study: NCT01783691
Drug: NKTT120
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02543060
Drug: cavity protection toothpaste
Normalized name: Aquafresh Cavity Protection Toothpaste
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.243% sodium fluoride toothpaste
Study: NCT00482664
Drug: CP-866,087
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets for oral administration
Study: NCT00482664
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets for oral administration
Study: NCT00409357
Drug: SL77.0499-10 (alfuzosin hydrochloride)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01934777
Drug: Docosahexaenoic Acid plus Vitamin E plus choline
Normalized name: cholecalciferol / docosahexaenoic acid / eicosapentaenoic acid / vitamin E Oral Capsule [Sea-Omega Plus D]
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA 250 mg plus Vitamin E (39 UI) plus Choline 201 mg
Study: NCT00524901
Drug: NaCl 0.9%
Normalized name: DEXTROSE 5%/NACL 0.9% INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of NaCl 0.9% during CABG for three vessel disease, 1 ml intravenously.
Study: NCT03682211
Drug: Fentanyl Citrate
Normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 μg/ml fentanyl citrate (Sublimaze, Janssen Cilag, Ltd, Marketing Authorisation No. PA 0748/044/001) administered intranasally using the MAD Nasal Intranasal Mucosal Atomiser Device
Study: NCT01519167
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 0.5 - 3 mcg/kg IV
Study: NCT02452515
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients will be treated orally with combinations of IR tablets containing placebo to achieve the indicated dosages.
Study: NCT00543530
Drug: MK0831
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02657785
Drug: R-IDARAM plus intrathecal chemotherapy
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-IDARAM comprised of rituximab 375 mg/m2 (day 1), idarubicin 10 mg/m2(day 2 and 3); dexamethasone 100 mg/m2 (12 h.infusion in day 2, 3 and 4); cytarabine 1 g/m2 (1 h. infusion in day 2 and 3); methotrexate 2 g/m2 (6 h. infusion in day 4 with folinic acid rescue). Intrathecal Immunochemotherapy comprised of rituximab 10mg, MTX 15mg, dexamethasone 5mg and Ara-c 50mg once a week.
Study: NCT01955629
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form: Tablets; Route of administration: Oral
Study: NCT02562664
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets taken twice daily continuously for three cycles.
Study: NCT02633696
Drug: silybin phosphatidylcholine
Normalized name: silybin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02633696
Drug: Legalón SIL
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00351871
Drug: PEG-Intron Plus REBETOL
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00571168
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules on day 1-4
Study: NCT02659397
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blinded ETC-1002-matched placebo tablet once daily for 4 weeks (Weeks 1 to 4)
Study: NCT02613026
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01415336
Drug: Doxorubicin, Cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: doxorubicin 60 mg/m², iv, day 1; Cyclophosphamide 600 mg/m², iv, day 1; every 3 weeks for 4 cycles
Study: NCT01415336
Drug: doxorubicin, Capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: doxorubicin 60 mg/m², iv, day 1; capecitabine 950 mg/m2, twice a day, via oral intake, day 1 to day 14; every 3 weeks for 4 cycles
Study: NCT03382340
Drug: Imx-110
Approvals — FDA: no, EMA: no, PMDA: no
Description: a nanoparticle encapsulating a Stat3/NF-kB/poly-tyrosine kinase inhibitor and low-dose doxorubicin
Study: NCT03323567
Drug: MD Muscle GUNA collagen
Approvals — FDA: no, EMA: no, PMDA: no
Description: intramusclular injections of MD Muscle collagen
Study: NCT03323567
Drug: Saline Solution, Hypertonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: intramuscular Saline injection
Study: NCT02940314
Drug: HIP1503
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02940314
Drug: HGP1103
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00504972
Drug: hLL1
Approvals — FDA: no, EMA: no, PMDA: no
Description: hLL1 administered intravenously once daily Monday through Friday for 2 consecutive weeks (10 total doses) at one of 4 planned dose levels: 1.5, 4, 6 or 8 mg/kg.
Study: NCT01526707
Drug: inhaled steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: inhaled budesonide for 7 days
Study: NCT00137891
Drug: Modified Release rhTSH
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02884713
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The primary objective was to evaluate the efficacy of the 10-day course of levofloxacin, doxycycline and esomeprazole in non-responders to first-line therapies for H. pylori eradication in Saudi Arabia. Secondary objectives included; symptoms response to treatment, factors associated with eradication of H. pylori and adverse events associated with the treatment
Study: NCT04079140
Drug: Dinoprostone
Normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) self-inserted by the patient 12 hours before IUD insertion.
Study: NCT04079140
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one tablet of placebo self-inserted by the patient 12 hours before IUD insertion.
Study: NCT01763840
Drug: Contrast enhanced Ultrasound
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound, then contrast enhanced ultrasound.
Study: NCT00031902
Drug: prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02587273
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In this study there will be no administration of an investigational product per study protocol. The dosage of fentanyl will be according to the ICU's established procedures and the treating physician's judgment. The specific dose of fentanyl given to each patient will differ extensively. By routine, the ICU's in our hospital usually dose the fentanyl infusion as 0,5 - 6 μg/kg/hrs (kg = Ideal Body Weight). The intervention in this study will be a per protocol cessation in administration of fentanyl over a 6 hours period. Arterial blood samples, urine samples, pre and post filter samples and samples from dialysate will be collected during this 6 hours. If the patient needs opioid analgesia during the period, alternative opioid analgesia will be given.
Study: NCT02496052
Drug: estradiol valerate tablets+dydrogesterone Tablets
Normalized name: dydrogesterone / estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral estradiol valerate tablets+dydrogesterone Tablets
Study: NCT02369172
Drug: ASP2151
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02860429
Drug: Cinobufacini injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: cinobufacini injection 20ml mixed with 5% Glucose injection 500ml started at the first day of chemotherapy until seven days once a day.
Study: NCT02860429
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy is the oxaliplatin combination with fluorouracil regimen.
Study: NCT02551549
Drug: CD101 IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: antifungal
Study: NCT02551549
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline
Study: NCT02093195
Drug: Symbicort turbuhaler
Normalized name: Symbicort Turbuhaler
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01821560
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00620503
Drug: Proellex 25 mg formulation B
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: One 25 mg Proellex capsule formulation B administered both fed and fasted
Study: NCT00811486
Drug: Spironolactone and conivaptan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, 50 mg to 200 mg, daily, orally 20 mg intravenously one time over 30 minutes
Study: NCT00610480
Drug: 1st visit Optive, then 2nd visit Systane
Approvals — FDA: no, EMA: no, PMDA: no
Description: First visit: Instillation of Optive followed by evaporometry assessment after 30 minutes.~Second visit: Instillation of Systane followed by evaporometry assessment after 30 minutes.
Study: NCT00610480
Drug: 1st visit Systane, then 2nd visit Optive
Approvals — FDA: no, EMA: no, PMDA: no
Description: First visit: Instillation of Systane followed by evaporometry assessment after 30 minutes.~Second visit: Instillation of Optive followed by evaporometry assessment after 30 minutes.
Study: NCT04326426
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT02908191
Drug: ABI-H0731
Normalized name: PICEA ABIES WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02908191
Drug: Placebo for ABI-H0731
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01458535
Drug: ABT-450
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets
Study: NCT01458535
Drug: ABT-267
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets
Study: NCT02719093
Drug: recombinant FSH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection
Study: NCT04549168
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet matched to lemborexant 10 mg tablet.
Study: NCT00470301
Drug: doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00470301
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02825979
Drug: Anti-Arrhythmic Drug Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrhythmic drug therapy (Class I - flecainide, propafenone; Class III - sotalol, dronedarone) will prescribed and monitored based on local clinical practice, and according to guideline-suggested drug management for symptomatic patients with paroxysmal AF.
Study: NCT03267199
Drug: Thrombolytic
Normalized name: THROMBOLYTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy
Study: NCT01564680
Drug: Lornoxicam
Normalized name: lornoxicam
DrugBank: Lornoxicam (DB06725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg at skin closure and 8 mg 12 hours postoperative
Study: NCT02464176
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine will be used in lumbar plexus nerve block mixture.